Literature DB >> 20004473

Early complement factors in the local tissue immunocomplex generated during intestinal ischemia/reperfusion injury.

Haekyung Lee1, Danielle J Green, Lawrence Lai, Yunfang Joan Hou, Jens C Jensenius, David Liu, Cheolho Cheong, Chae Gyu Park, Ming Zhang.   

Abstract

Recent work reveals that the innate immune system is able to recognize self-targets and initiate an inflammatory response similar to that of pathogens. One novel example of this innate autoimmunity is ischemia/reperfusion (I/R) injury, in which reperfusion of the ischemic tissues elicits an acute inflammatory response activated by natural IgM (nIgM) binding to ischemia-specific self-antigens, which are non-muscle myosin heavy chains type II (NMHC-II) subtype A and C. Subsequently, the complement lectin pathway is activated and eventually tissue injury occurs. Although earlier studies in the intestinal model showed that the classical complement pathway did not initiate I/R injury, C1q deposition was still observed in the local injured tissues by imaging analysis. Moreover, the involvement of the alternative complement pathway became unclear due to conflicting reports using different knockout mice. To explore the immediate downstream pathway following nIgM-ischemic antigen interaction, we isolated the nIgM-ischemic antigen immunocomplexes from the local tissue of animals treated in the intestinal I/R injury model, and examined the presence of initial molecules of three complement pathways. Our results showed that mannan-binding lectin (MBL), the early molecule of the lectin pathway, was present in the nIgM-ischemic Ag immunocomplex. In addition, C1q, the initial molecule of the classical pathway was also detected on the immunocomplex. However, Factor B, the early molecule in the alternative pathway, was not detected in the immunocomplex. To further examine the role of the alternative pathway in I/R injury, we utilized Factor B knockout mice in the intestinal model. Our results showed that Factor B knockout mice were not protected from local tissue injury, and their complement system was activated in the local tissues by nIgM during I/R. These results indicated that the lectin complement pathway operates immediately downstream of the nIgM-ischemic antigen interaction during intestinal I/R. Furthermore, the classical complement pathway also appears to interact with the of nIgM-ischemic antigen immunocomplex. Finally, the alternative complement pathway is not involved in I/R injury induction in the current intestinal model. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004473      PMCID: PMC2815171          DOI: 10.1016/j.molimm.2009.11.022

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  46 in total

1.  Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly.

Authors:  Dirk Spitzer; Lynne M Mitchell; John P Atkinson; Dennis E Hourcade
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

2.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.

Authors:  Hong Xiao; Adrian Schreiber; Peter Heeringa; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 3.  Homeostatic roles of naturally occurring antibodies: an overview.

Authors:  Hans U Lutz
Journal:  J Autoimmun       Date:  2007-09-12       Impact factor: 7.094

Review 4.  Natural antibody mediated innate autoimmune response.

Authors:  Ming Zhang; Michael C Carroll
Journal:  Mol Immunol       Date:  2006-07-28       Impact factor: 4.407

5.  The role of natural IgM in myocardial ischemia-reperfusion injury.

Authors:  Ming Zhang; Lloyd H Michael; Sandrine A Grosjean; Ralph A Kelly; Michael C Carroll; Mark L Entman
Journal:  J Mol Cell Cardiol       Date:  2006-06-16       Impact factor: 5.000

Review 6.  Natural antibodies, autoantibodies and complement activation in tissue injury.

Authors:  Sherry D Fleming
Journal:  Autoimmunity       Date:  2006-08       Impact factor: 2.815

7.  Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.

Authors:  Nirmal K Banda; Allyson K Wood; Kazue Takahashi; Brandt Levitt; Pauline M Rudd; Louise Royle; Jodie L Abrahams; Gregory L Stahl; V Michael Holers; William P Arend
Journal:  Arthritis Rheum       Date:  2008-10

8.  Human natural IgM can induce ischemia/reperfusion injury in a murine intestinal model.

Authors:  Ming Zhang; Elisabeth M Alicot; Michael C Carroll
Journal:  Mol Immunol       Date:  2008-07-30       Impact factor: 4.407

Review 9.  Natural IgM-mediated innate autoimmunity: a new target for early intervention of ischemia-reperfusion injury.

Authors:  Ming Zhang; Michael C Carroll
Journal:  Expert Opin Biol Ther       Date:  2007-10       Impact factor: 4.388

10.  A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.

Authors:  Yuxiang Huang; Fei Qiao; Carl Atkinson; V Michael Holers; Stephen Tomlinson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

View more
  13 in total

Review 1.  Ischemia/Reperfusion.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Compr Physiol       Date:  2016-12-06       Impact factor: 9.090

Review 2.  Cell biology of ischemia/reperfusion injury.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

3.  Unilateral uterine ischemia/reperfusion-induced bilateral fetal loss and fetal growth restriction in a murine model require intact complement component 5.

Authors:  Xiao-Wu Qu; Tamas Jilling; Mark G Neerhof; Kehuan Luo; Emmet Hirsch; Larry G Thaete
Journal:  J Reprod Immunol       Date:  2012-06-09       Impact factor: 4.054

4.  Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice.

Authors:  Andrew Elvington; Carl Atkinson; Liudmila Kulik; Hong Zhu; Jin Yu; Mark S Kindy; V Michael Holers; Stephen Tomlinson
Journal:  J Immunol       Date:  2011-12-23       Impact factor: 5.422

5.  Effect of complement C1q expression on hepatic ischemia-reperfusion injury in rats.

Authors:  Xiao-Bo Feng; Jian-Juan Ke; Yan Rao; Zong-Ze Zhang; Yan-Lin Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

6.  Delineating the relationships among the formation of reactive oxygen species, cell membrane instability and innate autoimmunity in intestinal reperfusion injury.

Authors:  Haekyung Lee; Eun Hee Ko; Mark Lai; Na Wei; Javi Balroop; Zerin Kashem; Ming Zhang
Journal:  Mol Immunol       Date:  2013-12-22       Impact factor: 4.407

7.  Conventional alpha beta (αβ) T cells do not contribute to acute intestinal ischemia-reperfusion injury in mice.

Authors:  Yi Yu; Xiaoyan Feng; Gertrud Vieten; Stephanie Dippel; Tawan Imvised; Faikah Gueler; Benno M Ure; Jochen F Kuebler; Christian Klemann
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

8.  Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury.

Authors:  Nicholas Chun; Ala S Haddadin; Junying Liu; Yunfang Hou; Karen A Wong; Daniel Lee; Julie I Rushbrook; Karan Gulaya; Roberta Hines; Tamika Hollis; Beatriz Nistal Nuno; Abeel A Mangi; Sabet Hashim; Marcela Pekna; Amy Catalfamo; Hsiao-Ying Chin; Foramben Patel; Sravani Rayala; Ketan Shevde; Peter S Heeger; Ming Zhang
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

9.  Which pathways trigger the role of complement in ischaemia/reperfusion injury?

Authors:  Conrad A Farrar; Elham Asgari; Wilhelm J Schwaeble; Steven H Sacks
Journal:  Front Immunol       Date:  2012-11-19       Impact factor: 7.561

Review 10.  Mannan-binding lectin in cardiovascular disease.

Authors:  Izabela Pągowska-Klimek; Maciej Cedzyński
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.